Search
Influenza B virus B/Phuket/3073/2013 recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10779ApprovedInvestigationalInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Fluarix Tetra Injektionssuspension in einer FertigspritzeSirolimus
go.drugbank.com/drugs/DB00877ApprovedInvestigational[A242417] Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. … [A1320] Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants.
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB10076ApprovedHaemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen is a vaccine for intramuscular injection used in the prevention of invasive disease caused by *Haemophilus … vaccine contains the *Haemophilus influenzae* type b capsular polysaccharide (polyribosyl-ribitol-phosphate, PRP), a high-molecular-weight polymer prepared from the *H. influenzae* type b strain 1482 grown in
Mixtures: Prohibit Inj Vaccine, PENTAXİM 0,5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇİN TOZ İÇEREN FLAKON VE SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETNitrous acid
go.drugbank.com/drugs/DB09112ApprovedInvestigationalIt is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. … There is also research to investigate its applicability towards treatments for heart attacks, brain aneurysms, pulmonary hypertension in infants, and Pseudomonas aeruginosa infections.
Categories: Compounds used in a research, industrial, or household settingDapagliflozin
go.drugbank.com/drugs/DB06292ApprovedInvestigational[A261601] Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise. … [L48251] It was later approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease in April
Categories: Drugs Used in DiabetesArbutamine
go.drugbank.com/drugs/DB01102ApprovedArbutamine, administered through a closed-loop, computer-controlled drug-delivery system, is indicated to elicit acute cardiovascular responses, similar to those produced by exercise, in order to aid in … diagnosing the presence or absence of coronary artery disease in patients who cannot exercise adequately .
Categories: Compounds used in a research, industrial, or household settingOlsalazine
go.drugbank.com/drugs/DB01250Approved[A257063] Olsalazine is used in the treatment of ulcerative colitis.[L45023,L45151] … [A257078] Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon.
Enalapril
go.drugbank.com/drugs/DB00584ApprovedInvestigationalVet approvedand renal reabsorption of sodium ions in the kidneys. … It is also found in a combination product containing [hydrochlorothiazide] that is used for the management of hypertension.
Categories: Agents Acting on the Renin-Angiotensin SystemSynonyms: (S)-1-(N-(1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline, 1-(N-((S)-1-carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl esterAtomoxetine
go.drugbank.com/drugs/DB00289ApprovedInvestigationalLong-acting formulations of psychostimulants (such as [DB00422], [DB01576], and [DB01255]) are typically considered the most effective and first-line treatment for ADHD in adults and children as recommended … [A18262] This is beneficial in the treatment of ADHD as DA activation in the subcortical NA and striatum is associated with many stimulant-associated side effects and an increase in abuse potential, which
Padeliporfin
go.drugbank.com/drugs/DB15575ApprovedInvestigational[A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799] … It aims to destroy only cancerous lesions of the prostate, rather than ablating the entire prostate gland.
Categories: Sensitizers Used in Photodynamic/radiation Therapy